A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT00739453
First received: August 19, 2008
Last updated: December 21, 2011
Last verified: December 2011

August 19, 2008
December 21, 2011
October 2008
August 2011   (final data collection date for primary outcome measure)
Determine the maximum tolerated dose (MTD) and recommended phase 2 dose of OSI-906 and erlotinib [ Time Frame: 21 days ] [ Designated as safety issue: No ]
Determine the maximum tolerated dose (MTD) and recommended phase 2 dose of OSI-906 and erlotinib [ Time Frame: 2.5 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00739453 on ClinicalTrials.gov Archive Site
Safety profile, Pharmacokinetic profile, pharmacodynamic activity, Preliminary antitumor activity [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
Safety profile, Pharmacokinetic profile, pharmacodynamic activity, Preliminary antitumor activity [ Time Frame: 2.5 ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
A Phase I Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®) in Patients With Advanced Solid Tumors

Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) of OSI-906 in combination with erlotinib

The study will open with Schedule 1 (S1), in which OSI-906 is administered on Days 1-3 every 7 days. Erlotinib will be administered daily starting on Day 2. A treatment period is defined as 21 days.

Initiation of Schedule 2 (S2), in which OSI-906 is administered daily starting on Day 1 and erlotinib is administered daily starting on Day 2, will occur after observation of clinically significant related toxicity >/= grade 2 in any patient on S1 or after > 2 dose levels in S1 have been examined without evidence of Dose Limiting Toxicities (DLT).

Initiation of Schedule 3 (S3), in which OSI-906 is administered twice daily starting on Day 1 and erlotinib is administered daily starting on Day 2, will occur after observation of clinically significant related toxicity >/= grade 2 in any patient on S2 or after > 2 dose levels in S2 have been examined without evidence of DLT.

Once the phase 2 dose has been established for S3, 1 expansion cohort will be opened.

The Expansion Cohort will enroll approximately 30 evaluable patients with stage IIIB/IV Non-small Cell Lung Carcinoma (NSCLC). Patients in the NSCLC Expansion Cohort will be required to have either archival tissue or fresh tumor tissue available at the start of study.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Advanced Solid Tumors
  • Drug: OSI-906
    administered orally
  • Drug: erlotinib
    administered orally
    Other Names:
    • Tarceva
    • OSI-774
  • Experimental: Schedule 1
    OSI-906 is administered on Days 1-3 every 7 days. Erlotinib will be administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.
    Interventions:
    • Drug: OSI-906
    • Drug: erlotinib
  • Experimental: Schedule 2
    OSI-906 is administered daily starting on Day 1 and erlotinib is administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.
    Interventions:
    • Drug: OSI-906
    • Drug: erlotinib
  • Experimental: Schedule 3
    OSI-906 is administered continuously twice daily starting on Day 1 and erlotinib is administered daily starting on Day 2. The NSCLC expansion cohort will follow Schedule 3 with the exception that erlotinib is administered daily starting on Day 8.
    Interventions:
    • Drug: OSI-906
    • Drug: erlotinib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
95
December 2011
August 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically confirmed advanced solid tumor
  • For the NSCLC Expansion Cohort, a confirmed diagnosis of stage IIIB/IV NSCLC after failure of at least 1 prior chemotherapy regimen is required
  • Patients with Eastern Cooperative Oncology Group (ECOG) performance status </= 2
  • Predicted life expectancy >/= 12 weeks
  • Patients may have had prior therapy, providing certain conditions are met:

    1. Chemotherapy: A minimum of 3 weeks (4 weeks for carboplatin or investigational anticancer agents and 6 weeks for nitrosoureas and mitomycin C) must have elapsed between the end of treatment and registration into this study. Patients must have recovered from any treatment-related toxicities (except for alopecia, fatigue, and grade 1 neurotoxicity) prior to registration.
    2. Hormonal therapy: Patients may have had prior anticancer hormonal therapy provided it is discontinued prior to registration into the study. However, patients with prostate cancer with evidence of progressive disease may continue on therapy that produces medical castration (eg, goserelin or leuprorelin), provided this therapy was commenced at least 3 months earlier.
    3. Radiation: Patients may have had prior radiation therapy provided they have recovered from the acute, toxic effects of radiotherapy prior to registration. A minimum of 21 days must have elapsed between the end of radiotherapy and registration into the study unless the radiation affected less than 25% of bone marrow.
    4. Surgery: Previous surgery is permitted provided that wound healing has occurred prior to registration.
  • Fasting glucose </= 125 mg/dL (7 mmol/L) at baseline and on Day 1 prior to dosing
  • Blood ketones </= Upper Limit of Normal (ULN)
  • Neutrophil count >/= 1.5 x 10^9/L
  • Platelets >/= 100 x 10^9/L
  • Bilirubin </= 1.5 x ULN
  • AST and/or ALT </= 2.5 x ULN or </= 5 x ULN if patient has documented liver metastases
  • Serum creatinine </= 1.5 x ULN
  • Patients must be nonsmokers (or former smokers who stopped smoking > 3 months previously) and have a negative cotinine test at baseline and on Day 1
  • Patients in the NSCLC Expansion Cohort must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)
  • Patients in the NSCLC Expansion Cohort will be required to have either an archival or fresh tumor tissue (whole or partial block) available at the start of study
  • Patients must be accessible for repeat dosing and follow-up, including pharmacokinetic sampling
  • Patients - both males and females - with reproductive potential must agree to practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test at baseline and on Day 1
  • Patients must provide verbal and written informed consent to participate in the study

Exclusion Criteria:

  • Documented history of diabetes mellitus
  • History of significant cardiac disease unless the disease is well-controlled. Significant cardiac diseases includes second/third degree heart block; significant ischemic heart disease; QTc interval > 450 msec at baseline; poorly controlled hypertension; congestive heart failure of New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea)
  • History of cerebrovascular accident (CVA) within 12 months prior to registration or that is not stable
  • Prior epidermal growth factor receptor (EGFR) or insulin like growth factor receptor (IGFR) inhibitor therapy, except for prior erlotinib therapy in the NSCLC Expansion Cohort, prior erlotinib therapy will not be exclusionary
  • History of any psychiatric condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide informed consent
  • Pregnant or breast-feeding females
  • Gastrointestinal (GI) abnormalities including inability to take oral medication, requirement for intravenous (IV) alimentation, active peptic ulcer, or prior surgical procedures affecting absorption
  • Ocular inflammatory or infectious condition that is not completely resolved prior to registration
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug
  • Any type of active seizure disorder
  • Use of drugs that have a risk of causing QT interval prolongation within 14 days prior to Day 1 dosing
  • Use of strong or moderate CYP3A4 or CYP1A2 inhibitors/inducers, with the exception of low-dose steroids, within 14 days prior to Day 1 dosing
  • Use of proton pump inhibitors within 14 days prior to day 1 dosing
  • Symptomatic brain metastases that are not stable, require steroids, or that have required radiation within the last 28 days
  • Active or uncontrolled infections or serious illnesses or medical conditions that could interfere with the patient's ongoing participation in the study
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   United Kingdom
 
NCT00739453
OSI-906-103, 2008-001743-20
No
Astellas Pharma Inc
Astellas Pharma Inc
Not Provided
Study Director: Sr. Medical Director Astellas Pharma Global Development
Astellas Pharma Inc
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP